Frankfurt
06.02.26 | 09:16
2,085 Euro
+7,47 % +0,145
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 1.228 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 282 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 22.01. | Advicenne: 2025 Full Year Sales | 304 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 20.01. | Advicenne: 2026 Financial Calendar | 265 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne's Sibnayal NDA For DRTA Tratement Accepted For Review By FDA | 2 | RTTNews | ||
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 218 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen | |
| 12.01. | Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal in European Union | 205 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 413 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | ADVICENNE: Advicenne has submitted to the US FDA the registration application (NDA) for Sibnayal in dRTA treatment | 4 | Euronext | ||
| 07.10.25 | ADVICENNE: Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities | 5 | Euronext | ||
| 19.09.25 | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 471 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08.25 | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 349 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07.25 | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 484 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07.25 | Advicenne Reports its H1 2025 Sales | 425 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07.25 | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 842 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| 02.07.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 426 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06.25 | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 458 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04.25 | Advicenne 2024 Universal Registration Document Made Available | 356 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03.25 | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 640 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,015 | -0,07 % | Opening Bell: Gold/Silber, PepsiCo, Merck & Co, Pfizer, PayPal, Teradyne, Uber/Snap/Alphabet, Nvidia | Die US-Börsen sind zum Wochenstart fester aus dem Handel gegangen. Der Dow Jones gewann 1,05 Prozent, der Nasdaq Composite legte 0,56 Prozent zu. Am Freitag hatte die mögliche Nominierung von Kevin... ► Artikel lesen | |
| ABBVIE | 189,20 | +0,11 % | Aktien New York Ausblick: Keine Tech-Erholung - Eli Lilly steigen kräftig | NEW YORK (dpa-AFX) - Mit Blick auf den Technologiesektor dürften sich die Investoren an den US-Börsen am Mittwoch zurückhalten. Der Nasdaq 100 Index, der am Vortag deutlich gefallen war, dürfte sich... ► Artikel lesen | |
| HAEMATO | 9,800 | +11,36 % | EQS-News: M1 Kliniken AG: Abschluss des Verkaufs der 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-News: M1 Kliniken AG
/ Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: Abschluss des Verkaufs der 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an... ► Artikel lesen | |
| HALEON | 4,610 | +0,11 % | Haleon gibt Gesamtzahl der Stimmrechte bekannt | ||
| LIGAND PHARMACEUTICALS | 160,00 | 0,00 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,385 | -5,97 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| ROYALTY PHARMA | 37,580 | -0,53 % | Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment | WASHINGTON (dpa-AFX) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million... ► Artikel lesen | |
| EISAI | 23,840 | -1,04 % | Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan | TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu... ► Artikel lesen | |
| TG THERAPEUTICS | 24,365 | 0,00 % | TG Therapeutics presents BRIUMVI data at ACTRIMS forum | ||
| DR REDDYS | 11,800 | 0,00 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| BETTERLIFE PHARMA | 0,039 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco | Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 11,000 | -3,51 % | WAVE Life Sciences stock price target raised to $43 from $40 at Canaccord | ||
| KYOWA KIRIN | 13,000 | +2,36 % | Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis | Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.Die neuartige Ausrichtung von Rocatinlimab als in der... ► Artikel lesen | |
| IGC PHARMA | 0,212 | -0,93 % | IGC Pharma, Inc.: IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation | POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment... ► Artikel lesen | |
| IMMUPHARMA | 0,055 | +2,80 % | Immupharma PLC - Attending JPMorgan Conference & Biotech Showcase |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.